Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UP-NEXT phase 3 maintenance trial of upifitamab rilsodotin in platinum-sensitive recurrent ovarian cancer
MOH_2023-01-24_012305Phase 3Not yet recruiting
- Sponsor
- Mersana Therapeutics
- Start
- Jan 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Upifitamab rilsodotin maintenance with Placebo maintenance (2 arms). Planned start Jan 2023; status: not yet recruiting.
02
Drugs
upifitamab rilsodotin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on MOH_2023-01-24_012305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-01-24_012305.